Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) saw a large drop in short interest in the month of May. As of May 29th, there was short interest totaling 17,200 shares, a drop of 71.4% from the May 14th total of 60,118 shares. Based on an average trading volume of 132,680 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Indaptus Therapeutics currently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Indaptus Therapeutics

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

Indaptus Therapeutics Price Performance

Shares of INDP stock traded up $0.01 during trading hours on Friday, reaching $3.58. 587,061 shares of the company’s stock were exchanged, compared to its average volume of 2,875,104. The company has a market cap of $405.40 million, a P/E ratio of -0.23 and a beta of 1.25. The company’s 50 day moving average is $2.27 and its two-hundred day moving average is $2.23. Indaptus Therapeutics has a 1 year low of $0.92 and a 1 year high of $19.91.

Indaptus Therapeutics (NASDAQ:INDP) last issued its earnings results on Friday, May 15th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.